Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001897612-25-000507
Filing Date
2025-11-07
Accepted
2025-11-07 13:02:38
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5886
  Complete submission text file 0001897612-25-000507.txt   7570
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Subject) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87705 | Film No.: 251461662
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1307 POINT STREET BALTIMORE MD 21231
Business Address 1307 POINT STREET BALTIMORE MD 21231 000-000-0000
T. Rowe Price Investment Management, Inc. (Filed by) CIK: 0001897612 (see all company filings)

EIN.: 854328500 | State of Incorp.: MD | Fiscal Year End: 1231
Type: SCHEDULE 13G/A